“…Despite the imperfect overlay between C-3 and C-4′ of febuxostat and techtochrysin, respectively, introducing a nitrile group at techtochrysin's C-4′ would still be a valid strategy to enhance the XO binding affinity due to the dynamic flexibility of active site. 57 To mimic this, a second possible direction for future optimization of techtochrysin as a novel XO inhibitor can be implemented by introducing a small hydrophobic angular substituent, such as methoxy group, at C-4′ to efficiently fill the XO hydrophobic subpocket, where the nitrile group resides, whilst retaining the hydrogen bond acceptor property to engage in a hydrogen bond with ASN768. The small lipophilic subpocket could still be able to accommodate this methoxy group with a small conformational shift due to the plasticity of the protein in molding the Mo-pt center to the shape of the ligand in the binding site, 58 and yet the XO inhibitory effect might be improved by fine-tuning modifications at 4′-position.…”
Section: Resultsmentioning
confidence: 99%
“… 57 To mimic this, a second possible direction for future optimization of techtochrysin as a novel XO inhibitor can be implemented by introducing a small hydrophobic angular substituent, such as methoxy group, at C-4′ to efficiently fill the XO hydrophobic subpocket, where the nitrile group resides, whilst retaining the hydrogen bond acceptor property to engage in a hydrogen bond with ASN768. The small lipophilic subpocket could still be able to accommodate this methoxy group with a small conformational shift due to the plasticity of the protein in molding the Mo-pt center to the shape of the ligand in the binding site, 58 and yet the XO inhibitory effect might be improved by fine-tuning modifications at 4′-position. Future optimization in the aforementioned directions is predicted to improve the techtochrysin's binding affinity, drug-likeness, and its subsequent XO inhibitory potential.…”
“…Despite the imperfect overlay between C-3 and C-4′ of febuxostat and techtochrysin, respectively, introducing a nitrile group at techtochrysin's C-4′ would still be a valid strategy to enhance the XO binding affinity due to the dynamic flexibility of active site. 57 To mimic this, a second possible direction for future optimization of techtochrysin as a novel XO inhibitor can be implemented by introducing a small hydrophobic angular substituent, such as methoxy group, at C-4′ to efficiently fill the XO hydrophobic subpocket, where the nitrile group resides, whilst retaining the hydrogen bond acceptor property to engage in a hydrogen bond with ASN768. The small lipophilic subpocket could still be able to accommodate this methoxy group with a small conformational shift due to the plasticity of the protein in molding the Mo-pt center to the shape of the ligand in the binding site, 58 and yet the XO inhibitory effect might be improved by fine-tuning modifications at 4′-position.…”
Section: Resultsmentioning
confidence: 99%
“… 57 To mimic this, a second possible direction for future optimization of techtochrysin as a novel XO inhibitor can be implemented by introducing a small hydrophobic angular substituent, such as methoxy group, at C-4′ to efficiently fill the XO hydrophobic subpocket, where the nitrile group resides, whilst retaining the hydrogen bond acceptor property to engage in a hydrogen bond with ASN768. The small lipophilic subpocket could still be able to accommodate this methoxy group with a small conformational shift due to the plasticity of the protein in molding the Mo-pt center to the shape of the ligand in the binding site, 58 and yet the XO inhibitory effect might be improved by fine-tuning modifications at 4′-position. Future optimization in the aforementioned directions is predicted to improve the techtochrysin's binding affinity, drug-likeness, and its subsequent XO inhibitory potential.…”
“…The compound having a nitro group on the meta position of the phenyl ring significantly increases the activity profile. 113 Figueiredo et al prepared trisubstituted barbiturates and thiobarbiturates and investigated their xanthine oxidase inhibitory activity. The test results highlighted that compound 50 with an IC 50 value of 24.3 μM was the most energetic molecule in the series.…”
Xanthine oxidase is a molybdo-flavoenzyme and isoform of xanthine dehydrogenase, both exist as xanthine oxidoreductase and responsible for purine catabolism. Xanthine oxidase is more involved in pathological conditions when extensively...
“…Compound 47 with NO 2 (electron-withdrawing group) on the meta position of benzene ring was found to be most potent. Molecular docking study suggested that the most potent compound 47 showed hydrogen bonds between the carbonyl group of the tropolone ring, a hydroxyl group bound to the molybdenum ion, and the NH group of Ala1079 as a backbone; (ii) a hydrogen bond between the acidic hydroxyl group of the tropolone ring and the guanidine group of Arg880, an electrostatic interaction between the nitro group on the benzene ring and the amino acid residue of Lys771 (Sato et al, 2018). Figueiredo et al synthesized a series of trisubstituted barbiturates and thiobarbiturates and evaluated them for their XO (bovine) inhibitory potential.…”
Inhibition of xanthine oxidase (XO) is an effective and most prominent therapeutic approach for the management of gout. Discovery of its association in the pathophysiology of diabetes, cardiovascular disorders, etc., widened its therapeutic horizons. Limited drug candidates in clinical practice along with side effects forced researchers to develop more efficacious and safer XO inhibitors for the management of gout and other disorders associated with XO hyperactivity. In this regard, this review focus on (a) various drug candidates in clinical practice and under clinical trials, (b) Development of various heterocyclic motifs as XO inhibitors in last two decades and (c) various patented synthetic XO inhibitors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.